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Background. HIV-infected individuals have an increased risk of avascular bone necrosis (AVN). Antiretroviral therapy (ART) 
and particularly protease inhibitors (PI) have been implicated as a risk factor. We aimed to study the associations of ART with the 
occurrence of AVN among Swiss HIV Cohort Study participants (SHCS).
Methods. We used incidence density sampling to perform a case control study within the Swiss HIV Cohort Study (SHCS) 
comparing prospectively collected AVN cases and controls by conditional logistic regression analysis. To evaluate the effect of ART, 
multivariable models were adjusted for HIV transmission risk group, age, alcohol consumption, use of corticosteroids, CD4 nadir, 
maximum viral load, and pancreatitis.
Results. We compared 74 AVN cases and 145 controls. Associations with AVN were shown for heterosexual HIV acquisition 
(odds ratio [OR], 3.4; 95% confidence interval [CI], 1.1–10), alcohol consumption (OR, 2.7; 95% CI, 1.3–5.7), and hyperlipidemia 
(OR, 3.6; 95% CI, 1.4–9.6). After adding ART substances to the multivariable base model, there was evidence of an association for 
treatment with tenofovir (TDF) >1 year (OR, 4.4; 95% CI, 1.4–14) with AVN. Neither exposure to specific frequently prescribed ART 
combinations or ART drug classes nor cumulative ART exposure showed any associations with AVN.
Conclusions. In the HIV-infected population, a combination of risk factors such as heterosexual HIV acquisition, moderate to 
severe alcohol intake, and hyperlipidemia seem to contribute to AVN. ART does not seem to be a relevant risk factor for AVN. The 
association of prolonged TDF exposure with AVN needs to be confirmed.
Keywords. antiretroviral therapy; avascular bone necrosis; HIV; tenofovir. 
With the introduction of modern antiretroviral therapy (ART), 
HIV infection has become a chronic condition, with the HIV-
infected population facing potential long-term drug toxicities 
and increasing co- and multimorbidity, along with the natural 
aging process [1, 2]. Furthermore, certain medical conditions 
are considerably more prevalent in HIV-infected persons com-
pared with the general population [3, 4], including avascular 
bone necrosis (AVN) [5, 6]. The pathogenesis of AVN seems 
to be related to ischemia of bone, with established risk factors 
including corticosteroid use, alcohol consumption, smoking, 
hyperlipidemia, hemodialysis, sickle cell disease, pancreatitis, 
collagen vascular disease, irradiation therapy, and hypercoag-
ulability [5–9].
Among HIV-positive persons, AVN incidence is up to 100 
times higher than in the general population, and, rarely, AVN 
occurs at multiple sites [7, 8, 10]. It remains unclear to what extent 
this is related to increased physician awareness of AVN [5, 6] or 
to prolonged survival of HIV-infected persons [11]. Along with 
other established risk factors, ART and especially protease inhib-
itors (PIs) have been implicated as risk factors for AVN, although 
by unknown mechanisms. Due to the rarity of AVN, no conclu-
sive link has emerged between HIV, ART, and AVN [6, 8–10, 12]. 
We aimed to study the association of different ART classes (PIs, 
non-nucleoside reverse transcriptase inhibitors [NNRTI], nucle-
oside reverse transcriptase inhibitor [NRTI]) and individual ART 
agents with the occurrence of AVN among Swiss HIV Cohort 
Study participants (SHCS). Extending our own series of 26 AVN 
cases published in 2004 [6], we now offer an updated analysis, 
with additional prospectively recorded AVN cases including 
detailed information on longitudinal alcohol intake and illicit 
drug exposure available for all SHCS participants.
MATERIALS AND METHODS
Data Source
The Swiss HIV Cohort Study (SHCS) is an observational 
study representative of >70% of adult HIV-infected persons in 
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Switzerland. At 6-monthly follow-up visits, demographic, clin-
ical, laboratory, and ART information has been prospectively 
recorded since 1988 [13]. In addition, the SHCS collects infor-
mation on comorbidities with central adjudication within the 
Data collection on Adverse events of Anti-HIV Drugs (D:A:D) 
Study framework [14]. Detailed information on bone-related 
events (AVN, osteoporosis, fractures with/without adequate 
trauma and DEXA scan) has been collected since 2008. The 
study was approved by local ethics committees, and written 
informed consent was obtained from all participants.
Definitions
There is no operational case definition for AVN in the medi-
cal literature. In our study, 67.6% AVN cases were diagnosed 
with magnetic resonance imaging (MRI) and the remaining 
cases with scintigraphy or x-ray. Body mass index (BMI; kg/m2) 
was categorized into <18.5 (underweight), 18.5–24.9 (normal), 
25–29.9 (overweight), and ≥30 (obese) [15]. Hyperlipidemia 
was defined as serum cholesterol level >5 mmol/L and/or a tri-
glyceride level >2 mmol/L. Alcohol use was stratified according 
to the World Health Organization definitions of severe (female 
>40  g/d, male >60  g/d), moderate (female 20–40  g/d, male 
40–60 g/d), and light (female <20 g/d, male <40 g/d). We dis-
tinguished 2 smoking categories (nonsmokers and ever/current 
smokers), and among the latter the number of pack-years was 
recorded. For cases and controls, information on the use of cor-
ticosteroids (yes/no, use of corticosteroids ≥3 months, dosage 
of corticosteroids) [16, 17], testosterone (yes/no), and anabolic 
steroids (yes/no) was obtained from medical records.
Information on HIV infection included presumed mode of 
HIV transmission; era of HIV diagnosis; duration of HIV infec-
tion at diagnosis of AVN; CD4 cell count and log10 HIV RNA 
at diagnosis of AVN; nadir CD4 cell count; log10 HIV RNA 
maximum value and exposure to drug classes including pro-
tease inhibitors; non-nucleoside reverse transcriptase inhibitor 
(NNRTI); nucleoside reverse transcriptase inhibitor (NRTI)– 
and integrase inhibitor (INI)–based ART combinations; indi-
vidual drugs including didanosine (DDI), stavudine (d4T), 
zidovudine (AZT), abacavir (ABC), lamivudine (3TC), emtric-
itabine (FTC), tenofovir (TDF), saquinavir (SQV), ritonavir 
(RTV), nelfinavir (NFV), lopinavir (LPV), indinavir (IDV), 
darunavir (DRV), atazanavir (ATV), nevirapine (NVP), efa-
virenz (EFV), and raltegravir (RGV); and most commonly pre-
scribed drug regimens (3TC/AZT/LPV/RTV, FTC/TDF/LPV/
RTV, 3TC/ABC/LPV/RTV, FTC/TDF/ATV/RTV, FTC/TDF/
DRV/RTV, FTC/TDF/EFV) in years.
Study Participants
Twenty-five out of the 26 patients from our 2004 publication on 
AVN [6] and 55 additional prospective cases of AVN were iden-
tified within the SHCS. Since our first analysis, AVN cases have 
accumulated 10 additional years of ART exposure with a large 
number of individual drugs. We performed incidence density 
sampling to identify controls. In detail: For each case with con-
firmed AVN, we randomly selected SHCS participants without 
any signs of AVN and matched these controls for gender, SHCS 
registration date (within –6/+12 months of the registration of 
corresponding cases) and last follow-up date (last follow-up 
date after the date of AVN diagnosis of the corresponding case). 
Medical charts of both cases and controls were reviewed by the 
treating physician using a standardized questionnaire to vali-
date the AVN diagnoses and complete risk factors, which were 
not part of the standard SHCS questionnaires. These additional 
risk factors included use of megestrol acetate, testosterone, cor-
ticosteroids, hypercoagulability, pulmonary embolism, deep 
vein thrombosis, pancreatitis, sickle cell anemia, radiation, col-
lagenosis, and hemodialysis. After excluding unvalidated cases 
and their respective controls, we analyzed 74 well-documented 
cases of AVN and 145 controls (Supplementary Figure 1).
Statistical Analysis
Characteristics were measured at the date of AVN diagnosis 
in cases and at the SHCS visit closest to this date in controls. 
Differences between cases and controls were analyzed by the 
chi-square test for categorical variables and by the Kruskal-
Wallis test for continuous variables. We assessed factors associ-
ated with AVN by the use of uni- and multivariable conditional 
logistic regression analysis. Factors with a P < .2 were included 
in the multivariable models. Final models were adjusted for 
HIV transmission risk group, age, alcohol consumption, use of 
corticosteroids, CD4 nadir, maximum viral load, pancreatitis, 
hyperlipidemia, smoking >20 pack-years, and use of testoster-
one. We used Stata/SE (version 14.2, StataCorp, College Station, 
Texas) for analyses.
RESULTS
We analyzed 219 SHCS participants, 74 with AVN and 145 con-
trols. Of 74 AVN cases, 4 (5%) were diagnosed before 1997, 20 
(27%) between 1997 and 2002, and 50 (68%) between 2002 and 
2014. AVN was located in the femoral head in 59 (80%) par-
ticipants, in the shoulder in 3 (4%), and in another bone in 11 
(15%). One participant concomitantly had AVN in the shoulder 
and in the femoral head.
Baseline Characteristics
Characteristics of participants are shown in Table 1. Compared 
with controls, participants with AVN were more likely to be 
intravenous drug users (IDUs) or to have acquired HIV heter-
osexually. In addition, they were more likely to have used corti-
costeroids for more than 3 months, to have hyperlipidemia, to 
drink alcohol, or to have experienced pancreatitis in the past; 
54% of the cases and 42% of the controls were smokers with 
>20 pack-years. The median durations of HIV infection among 
cases and controls were 12.6 years (interquartile range [IQR], 
5.4–19 years) and 13 years (IQR, 7.0–18 years), respectively. 
There was a trend for lower nadir CD4 cell counts among cases 
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Table 1. Characteristics of Participants With Avascular Bone Necrosis and Controls
Baseline Characteristics Total (n = 219) Cases With AVN (n = 74) Controls (n = 145) P Value
Sex
 Male, n (%) 162 (74) 55 (74) 107 (74) naa
Registration date in SHCS, median year (IQR) 1996 (1991–1999) 1996 (1991–1999) 1996 (1991–1999) naa
Follow-up until diagnosis of AVN, median (IQR), y 8.3 (4.0–15) 8.5 (3.8–15) 8.1 (4.2–15) naa
Race
 White, n (%) 200 (91) 66 (89) 134 (92) .44
HIV transmission risk group .003
 Men who have sex with men, n (%) 94 (43) 22 (30) 72 (50)
 Heterosexual, n (%) 61 (28) 27 (36) 34 (23)
 Injection drug use, n (%) 64 (29) 25 (34) 39 (27)
Age at diagnosis of AVN, median (IQR), y 45 (38–53) 42 (37–52) 46 (38–53) .29
Year of diagnosis .66
 <1997, n (%) 12 (5.5) 4.0 (5.4) 8.0 (5.5)
 1997–2002, n (%) 55 (25) 20 (27) 35 (24)
 >2002, n (%) 152 (69) 50 (68) 102 (70)
Smoking .08
 <20 pack-years, n (%) 118 (54) 34 (46) 84 (58)
 ≥20 pack-years, n (%) 101 (46) 40 (54) 61 (42)
BMI at diagnosis of AVN, median (IQR), kg/m2 24 (23–25) 24 (23–25) 24 (23–25) .72
Alcohol consumption .001
 None/light, n (%) 150 (68) 40 (54) 110 (76)
 Moderate/severe, n (%) 69 (32) 34 (46) 35 (24)
Comorbidities
 Diabetes mellitus, n (%) 19 (8.7) 5.0 (6.8) 14 (9.7) .445
 Hypertension, n (%) 64 (29) 20 (27) 44 (30) .62
 Hyperlipidemia, n (%) 164 (75) 64 (86) 100 (69) .002
 Pancreatitis, n (%) 9.0 (4.1) 6.0 (8.0) 3.0 (2.0) .05
 Pulmonary embolism/deep venous thrombosis, n (%) 18 (8.2) 8.0 (11) 10 (6.9) .308
 Radiation therapy, n (%) 9.0 (4.1) 2.0 (2.7) 7.0 (4.8) .49
 Haemodialyis, n (%) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) na
 Collagenosis, n (%) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) na
 Sickle cell anemia, n (%) 0.0 (0.0) 0.0 (0.0) 1 .0 (1.0) na
Co-infections
 CMV-seropositive, n (%) 169 (79) 56 (76) 113 (80) .441
 Toxoplasmosis-seropositive, n (%) 91 (43) 30 (41) 61 (44) .69
 HBs-Ag positive, n (%) 16 (7.6) 7.0 (9.7) 9.0 (6.5) .289
 HCV seropositive, n (%) 73 (33) 28 (38) 45 (31) .361
Comedications
 Corticosteroid use, n (%) 60 (27) 24 (32) 36 (25) .23
 Corticosteroid use >3 mo, n (%) 17 (7.8) 11 (15) 6.0 (4.1) .009
 Testosterone/anabolics use, n (%) 12 (5.5) 2.0 (2.7) 10 (6.9) .24
 Megestrol acetate use, n (%) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) na
AIDS at diagnosis of AVN, n (%) 71 (32) 30 (41) 41 (28) .093
CD4+ T-cell count
 CD4 count at diagnosis of AVN, median (IQR), cells/uL 431 (295–587) 398 (259–547) 460 (329–610) .33
 CD4 nadir, median (IQR), cells/uL 141 (57–250) 117 (38–200) 160 (70–265) .20
 CD4 nadir <200 cells/uL, n (%) 144 (66) 55 (74) 89 (61) .05
HIV-RNA
HIV RNA at diagnosis of AVN below detection limit, n (%) 140 (66) 45 (63) 95 (67) .49
RNA first value, median (IQR), log10 RNA 4.5 (3.7–5.1) 4.5 (3.5–5.2) 4.5 (3.8–5.0) .52
RNA maximum value, median (IQR), log10 RNA 5.0 (4.3–5.4) 5.1 (4.5–5.7) 5.0 (4.3–5.2) .17
RNA AUC, median (IQR), log10 copy-years 40 (24–60) 43 (25–62) 39 (24–58) .89
HIV treatment
Duration of HIV infection at diagnosis of AVN, median (IQR), y 13 (6.2–19) 13 (5.6–19) 13 (7.2–19) .07
Duration of untreated HIV infection at diagnosis of AVN, median (IQR), y 6.4 (1.5–10) 6.1 (1.1–9.7) 6.8 (1.9–11) .34
Alcohol use: severe (female >40 g/d, male >60 g/d), moderate (female 20–40 g/d, male 40–60 g/d), light (female <20 g/d, male <40 g/d). Hyperlipidemia: cholesterol >5 mmol/L and/or 
triglyceride >2 mmol/L.
Abbreviations: 3TC, lamivudin; ABC, abacavir; ART, antiretroviral treatment; ATV, atazanavir; AVN, avascular necrosis; AZT, zidovudine; d4T, stavudin; DDI, didanosin; DRV, darunavir; EFV, 
efavirenz; ETC, emtricitabine; FI, fusion inhibitor; HIV, human immunodeficiency virus; IDV, indinavir; IQR, interquartile range; LPV, lopinavir; NFV, nelfinavir; NNRTI, non-nucleoside reverse 
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RGV, raltegravir; RNA, ribonucleic acid; RTV, ritonavir; SQV, saquinavir; TDF, 
tenofovir.
aWe did not analyze factors that were matched on.
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compared with controls. Median exposure time to NRTI-, PI-, 
or NNRTI-based ART regimens was similar in both groups. 
Compared with controls, previous use of 3TC and TDF was 
more common among AVN cases (P < .05) (Table 2).
Overall Associations With Avascular Necrosis
There was no association of AVN with advancing age and BMI. 
An univariable association with AVN was recorded for hetero-
sexual or IDU acquisition of HIV, moderate/severe alcohol con-
sumption, pancreatitis, hyperlipidemia, and corticosteroid use 
≥3 months. There was a trend of an association with CD4 nadir 
<200 cellsµ/L (OR, 1.9; 95% CI, 0.99–3.7), maximum HIV-1 
viral load (OR, 3.6; 95% CI, 0.89–15), and >20 pack-years of 
smoking (OR, 1.6; 95% CI, 0.94–2.7).
In adjusted models (Table 3; Figure 1), associations of AVN were 
documented with heterosexual HIV acquisition (OR, 3.4; 95% CI, 
1.1–10), alcohol consumption (OR, 2.7; 95% CI, 1.3–5.7), hyperlipi-
demia (OR, 3.6; 95% CI, 1.4–9.6), and corticosteroid use <3 months 
(OR, 3.4; 95% CI, 0.97–12, trend). Other associations with AVN 
were no longer significant after mutual adjustment (CD4 nadir < 
200 cells/µL: OR, 1.4; 95% CI, 0.63–3.2; maximum HIV RNA: OR, 
1.6; 95% CI, 0.41–6.6; and pancreatitis: OR, 3.0; 95% CI, 0.66–14).
Associations of ART and Avascular Necrosis
Univariable associations with AVN were present for exposure to 
3TC <1 year (OR, 6.8; 95% CI, 1.6–28) and TDF >1 year (OR, 
3.5; 95% CI, 1.3–10) (Table  3). There was a trend toward an 
association with exposure to ATV >1  year (OR, 2.2; 95% CI, 
0.98–4.8). Neither exposure to the most frequently prescribed 
ART combinations (3TC/AZT/LPV, ETC/TDF/LPV, 3TC/
ABC/LPV, ETC/TDF/ATV, ETC/TDF/DRV, ETC/TDF/EFV, 
3TC/ABC/EFV) nor exposure to individual drug classes (PIs, 
NRTIs, NNRTIs, FIs) or cumulative duration of ART exposure 
showed a univariable association with AVN.
By adding ART agents to the multivariable base model 
(Figure 1), there was an association for treatment with TDF >1 
year (OR, 4.4; 95% CI, 1.4–14) and ever vs never use of TDF 
(OR, 3.5; 95% CI, 1.2–10). There was no evidence of an associ-
ation for cumulative use (per year), current use of TDF, or use 
of regimens containing TDF. Further, there were trends toward 
an association with exposure to 3TC <1 year (OR, 5.1; 95% CI, 
0.92–28), cumulative 3TC use (OR, 0.88; 95% CI, 0.76–1.0), and 
cumulative ABC use (OR, 0.86; 95% CI, 0.72–1.0). No further 
significant associations were seen for use of any ART, other 
ART substances, or ART drug classes.
DISCUSSION
In this case control study with 74 cases and 145 controls, nested 
in a prospective cohort study, we found an association of AVN 
with heterosexual HIV acquisition, moderate/severe alcohol 
consumption, hyperlipidemia, and a trend for corticosteroid 
use. These risk factors are also established for osteoporosis and 
osteoporotic fractures [18, 19], which hints toward a potential 
Table 2. Exposure to Antiretroviral Therapy
ART Substance, 
Regimen, 
or Drug Class
Total
Cases With 
AVN Controls
P Valuea P Valuebn = 219 n = 74 n = 145
ETC .75 .82
 Never, n (%) 157 (72) 53 (72) 104 (72)
 <1 y, n (%) 15 (6.9) 4.0 (5.4) 11 (7.6)
 ≥1 y, n (%) 47 (21) 17 (23) 30 (21)
DDI .70 .93
 Never, n (%) 117 (53) 40 (54) 77 (53)
 <1 y, n (%) 35 (16) 10 (14) 25 (17)
 ≥1 y, n (%) 67 (31) 24 (32) 43 (30)
DDC .36 .30
 Never, n (%) 186 (85) 66 (89) 120 (83)
 ≥1 y, n (%) 15 (6.8) 3.0 (4.1) 12 (8.3)
 >1 y, n (%) 18 (8.2) 5.0 (6.8) 13 (9)
D4T .57 .71
 Never, n (%) 109 (50) 39 (53) 70 (48)
 <1 y, n (%) 27 (12) 7.0 (9.5) 20 (14)
 ≥1 y, n (%) 83 (38) 28 (38) 55 (38)
AZT .53 .11
 Never, n (%) 54 (25) 16 (22) 38 (26)
 <1 y, n (%) 34 (16) 14 (19) 20 (14)
 ≥1 y, n (%) 131 (60) 44 (59) 87 (60)
ABC .59 .036
 Never, n (%) 150 (68) 54 (73) 96 (66)
 <1 y, n (%) 14 (6.4) 4.0 (5.4) 10 (6.9)
 ≥1 y, n (%) 55 (25) 16 (22) 39 (27)
3TC .011 .044
 Never, n (%) 49 (22) 11 (15) 38 (26)
 <1 y, n (%) 17 (7.8) 10 (14) 7.0 (4.8)
 ≥1 y, n (%) 153 (70) 53 (72) 100 (69)
TDF .032 .34
 Never, n (%) 123 (56) 36 (49) 87 (60)
 <1 y, n (%) 17 (7.8) 6.0 (8.1) 11 (7.6)
 ≥1 y, n (%) 79 (36) 32 (43) 47 (32)
SQV .77 .93
 Never, n (%) 169 (77) 56 (76) 113 (80)
 <1 y, n (%) 19 (8.7) 8.0 (11) 11 (7.6)
 ≥1 y, n (%) 31 (14) 10 (14) 21 (15)
RTV .58 .70
 Never, n (%) 186 (85) 61 (82) 125 (86)
 <1 y, n (%) 20 (9.1) 7.0 (9.5) 13 (9.0)
 ≥1 y, n (%) 13 (5.9) 6.0 (8.1) 7.0 (4.8)
NFV .15 .09
 Never, n (%) 134 (61) 49 (66) 85 (59)
 <1 y, n (%) 24 (11) 10 (14) 14 (9.7)
 ≥1 y, n (%) 61 (28) 15 (20) 46 (32)
LPV .11 .34
 Never, n (%) 161 (74) 50 (68) 111 (77)
 <1 y, n (%) 16 (7.3) 9.0 (12) 7.0 (4.8)
 ≥1 y, n (%) 42 (19) 15 (20) 27 (19)
IDV .39 .95
 Never, n (%) 135 (62) 42 (57) 93 (64)
 <1 y, n (%) 28 (13) 12 (16) 16 (11)
 ≥1 y, n (%) 56 (26) 20 (27) 36 (25)
DRV .98 .87
 Never, n (%) 205 (94) 69 (93) 136 (94)
 <1 y, n (%) 3.0 (1.4) 1.0 (1.4) 2.0 (1.4)
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similarity of risk factors for AVN and osteoporosis in HIV-
seropositive persons. We did not find evidence for an associ-
ation of AVN with any ART exposure except for a TDF signal.
Heterosexual HIV acquisition was associated with AVN 
in our study. This finding is possibly mediated by advanced 
immunosuppression, considering the fact that heterosexual 
participants of our study were more likely to be late present-
ers compared with other transmission groups (data not shown) 
[6]. This hypothesis was supported by a univariable association 
of AVN with a CD4 nadir >200 cells/µL and corticosteroid use 
>3  months. Prolonged corticosteroid treatment is more often 
used in late presenters (eg, as adjunctive treatment to opportun-
istic infections) or subsequent to ART start (eg, management of 
immune reconstitution inflammatory syndrome) [5, 6, 10, 12, 
20, 21]. In contrast to other studies, we did not observe an asso-
ciation with the use of testosterone or megestrol acetate. Alcohol 
use has previously been reported as a risk factor for AVN among 
HIV-positive persons [6, 10, 20, 21]. The longitudinal design of 
the SHCS including our quantitative assessment of alcohol con-
sumption at 6-monthly intervals in the SHCS since 2008 [13] 
allowed us to extend these findings. We confirmed that, com-
pared with light alcohol consumption, participants with moder-
ate/heavy alcohol use were more likely to experience AVN. We 
found an association of AVN with hyperlipidemia in our study 
population. Altered lipid metabolism may be present in the set-
ting of HIV, hence promoting bone ischemia and osteonecrosis 
[21]. Indeed, HIV-positive persons tend to drink more alcohol 
[22], to smoke more [23], and to have higher lipid levels [24] 
compared with the general population. Thus, HIV-positive per-
sons might be prone to AVN because of an unfavorable lifestyle 
profile [5, 8, 21]. Of note, a history of pancreatitis, which can be 
a late sequel of both chronic alcohol intake and hyperlipidemia 
[21], was also associated with AVN in the univariate model.
ART Substance, 
Regimen, 
or Drug Class
Total
Cases With 
AVN Controls
P Valuea P Valuebn = 219 n = 74 n = 145
 ≥1 y, n (%) 11 (5.0) 4.0 (5.4) 7.0 (4.8)
ATV .15 .25
 Never, n (%) 161 (74) 50 (68) 111 (77)
 <1 y, n (%) 13 (5.9) 4 (5.4) 9 (6.2)
 ≥1 y, n (%) 45 (21) 20 (27) 25 (17)
NVP .13 .17
 Never, n (%) 184 (84) 67 (91) 117 (81)
 <1 y, n (%) 15 (6.8) 2.0 (2.7) 13 (9.0)
 ≥1 y, n (%) 20 (9.1) 5.0 (6.8) 15 (10)
EFV .72 .24
 Never, n (%) 124 (57) 40 (54) 84 (58)
 <1 y, n (%) 30 (14) 10 (14) 20 (14)
 ≥1 y, n (%) 65 (30) 24 (32) 41 (28)
RGV .90 .37
 Never, n (%) 209 (95) 70 (95) 139 (96)
 <1 y, n (%) 5.0 (2.3) 2.0 (2.7) 3.0 (2.1)
 ≥1 y, n (%) 5.0 (2.3) 2.0 (2.7) 3.0 (2.1)
3TC/AZT/LPV/RTV .24 .12
 Never, n (%) 199 (91) 64 (87) 135 (93)
 <1 y, n (%) 11 (5.0) 5.0 (6.8) 6.0 (4.1)
 ≥1 y, n (%) 9.0 (4.1) 5.0 (6.8) 4.0 (2.8)
ETC/TDF/LPV/RTV .07 .32
 Never, n (%) 210 (96) 71 (96) 139 (96)
 <1 y, n (%) 4.0 (1.8) 0.0 (0.0) 4.0 (2.8)
 ≥1 y, n (%) 5.0 (2.3) 3.0 (4.1) 2.0 (1.4)
3TC/ABC/LPV/RTV .54 .37
 Never, n (%) 213 (97) 73 (99) 140 (97)
 <1 y, n (%) 1.0 (0.5) 0.0 (0) 1.0 (0.69)
 ≥1 y, n (%) 5.0 (2.5) 1.0 (1.4) 4.0 (2.8)
ETC/TDF/ATV/RTV .75 .26
 Never, n (%) 194 (89) 64 (86) 130 (90)
 <1 y, n (%) 8.0 (3.7) 3.0 (4.1) 5.0 (3.4)
 ≥1 y, n (%) 17 (7.8) 7.0 (9.5) 10 (6.9)
ETC/TDF/DRV/RTV .30 .45
 Never, n (%) 213 (97) 73 (99) 140 (97)
 <1 y, n (%) 3.0 (1.4) 1.0 (1.4) 2.0 (1.4)
 ≥1 y, n (%) 3.0 (1.4) 0.0 (0.0) 3.0 (2.1)
ETC/TDF/EFV .92 .37
 Never, n (%) 202 (92 69 (93) 133 (92)
 <1 y, n (%) 4.0 (1.8 1.0 (1.4) 3.0 (2.1)
 ≥1 y, n (%) 13 (5.9) 4.0 (5.4) 9.0 (6.2)
3TC/ABC/EFV .79 .77
 Never, n (%) 207 (95 69 (93.) 138 (95)
 <1 y, n (%) 3.0 (1.4 1.0 (1.4) 2.0 (1.4)
 ≥1 y, n (%) 9.0 (4.1) 4.0 (5.4) 5.0 (3.4)
NRTI .74 .16
 Never, n (%) 19 (8.7) 6.0 (8.1) 13 (9.0)
 <1 y, n (%) 13 (5.9) 4.0 (5.4) 9.0 (6.2)
 ≥1 y, n (%) 187 (83) 64 (86) 123 (85)
NNRTI .43 .049
 Never, n (%) 102 (47) 32 (43) 70 (48)
 <1 y, n (%) 25 (11) 11 (15) 14 (9.7)
 ≥1 y, n (%) 92 (42) 31 (42) 61 (42)
PI .65 .63
 Never, n (%) 45 (21) 13 (18) 32 (22)
ART Substance, 
Regimen, 
or Drug Class
Total
Cases With 
AVN Controls
P Valuea P Valuebn = 219 n = 74 n = 145
 <1 y, n (%) 17 (7.8) 7.0 (9.5) 10 (6.9)
 ≥1 y, n (%) 157 (72) 54 (73) 103 (71)
ART .74 .217
 Never, n (%) 19 (8.7) 6.0 (8.1) 13 (9.0)
 <1 y, n (%) 13 (5.9) 4.0 (5.4) 9.0 (6.2)
 ≥1 y, n (%) 187 (85) 64 (86) 123 (85)
Abbreviations: 3TC, lamivudin; ABC, abacavir; ART, antiretroviral treatment; ATV, atazanavir; 
AVN, avascular necrosis; AZT, zidovudine; d4T, stavudin; DDI, didanosin; DRV, darunavir; 
EFV, efavirenz; ETC, emtricitabine; FI, fusion inhibitor; HIV, human immunodeficiency virus; 
IDV, indinavir; IQR, interquartile range; LPV, lopinavir; NFV, nelfinavir; NNRTI, non-nucleo-
side reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, 
nevirapine; PI, protease inhibitor; RGV, raltegravir; RNA, ribonucleic acid; RTV, ritonavir; 
SQV, saquinavir; TDF, tenofovir.
aGlobal P value across the 3 categories never, <1 year, ≥1 year (from conditional logistic 
regression analysis).
bP value ever versus never (from conditional logistic regression analysis).
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Recently, investigators from EuroSIDA published a study on 
fractures (n = 496) and osteonecrosis (n = 73, 12 of whom were 
also included in our study), but when compared with our study, 
it identified quite a different set of risk factors for AVN: white 
race, lower nadir CD4, prior fracture/osteonecrosis, and prior 
AIDS [25]. We found some signal for CD4-nadir in the univari-
able model but not with AIDS. We have therefore decided not to 
include the latter in the final multivariable models, also to avoid 
overfitting because both parameters were strongly correlated 
(P < .001). Other differences are probably explained by the lim-
ited availability of well-known risk factors such as use of alcohol 
and corticosteroids in the EuroSIDA study [25]. Further, differ-
ent methodological approaches with a case-control design in our 
study and a time-to-event analysis with GEE models, including 
multiple end points and an arbitrary baseline in January 2004 in 
the EuroSIDA study, may also have contributed to the observed 
differences. EuroSIDA found associations for AVN with the ever 
vs never use of DDI, IDV, SQV, LPV/r (all P  <  .05), and TDF 
(P  =  .051) when analyzed individually but not when mutually 
adjusted for other drugs. In our study, only the 2 TDF exposures 
ever vs never (P =  .024) and never vs <1 year vs ≥1 year of use 
(P =  .022) were associated with an increase of AVN. There was 
no evidence of an association for cumulative use (per year), cur-
rent use of TDF, or use of regimens containing TDF. Of note, the 
power to detect signals of more recently introduced drugs were 
limited because one-third of AVN diagnoses were made before 
2002 (Table  1), when TDF was approved for clinical use. The 
current clinical situation is quite different than the pre-ART and 
early-ART era. Hence, the significance of the isolated finding for 
TDF, the association of AVN with prior fractures [25] and osteo-
porosis [26], remains to be elucidated in future studies. It might be 
speculated that once bone damage has occurred (ie, diminished 
bone mineral density of any origin), the bone will be more prone 
to ischemia and hence occurrence of AVN [26]. In addition, a sub-
normal regenerative capacity of osteoblasts has been postulated as 
a common feature of osteoporosis and AVN [26]. Of note, in the 
subset of patients with available DEXA scans in our study (n = 55), 
cases were more likely to have a lower bone mineral density com-
pared with controls (data not shown). Therefore, emphasis should 
be placed on maintaining bone health with optimization of vita-
min D and calcium intake in HIV-infected persons, in particular 
whenever prolonged corticosteroid treatment is initiated.
Prolonged use of ART, particularly exposure to protease 
inhibitors, has also been implicated as a potential AVN risk fac-
tor, possibly via PI-aggravated dyslipidemia (especially hyper-
triglyceridemia) and impaired circulation [18, 19]. A recently 
published meta-analysis [18, 19] on 68 AVN cases and 126 con-
trols showed an increased odds ratio for AVN among PI-exposed 
HIV-infected patients. In contrast to this meta-analysis, we did 
not find an association with any PI except for a weak ATV (ATV 
> 1 year: OR, 2.4; 95% CI, 0.86–6.4) and NFV signal (NVF ever 
vs never use, 2.4: 95% CI, 0.86–6.4).
Strengths of our study include a detailed chart review for 
both cases and controls with ascertainment of AVN diagnoses, 
validation and completion of risk factors collected in the SHCS 
(demographics; alcohol, nicotine, and drug use; lipids; CD4; 
HIV-1 RNA; ART), and identifying additional risk factors (eg, 
corticosteroid, testosterone, and megesterolacetate use; radiation 
therapy; collagenosis; hypercoagulability; pancreatitis; sickle cell 
anemia; radiation; and hemodialysis). Due to the completeness of 
the SHCS database, we were also able to control for ART expo-
sure itself, exposure to specific ART substances and ART groups. 
Our study has also some limitations. We could not analyze time 
trends in the occurrence of AVN because of the incidence density 
matching. Simultanously, incidence density matching is a strength 
of the current study as we had controls with contemporary ART. 
As our study has a case-control design, recorded data are sub-
ject to observation bias [27]. The association of AVN with HET 
remains partially unexplained. Bivariable analyses with all avail-
able potential confounders did not reveal relevant reductions in 
the associations of HET with AVN. Therefore, we cannot exclude 
residual confounding. We performed numerous analyses looking 
at all individual drugs (n  =  18) and the 7 most frequently pre-
scribed combination regimens without Bonferroni corrections. 
Thus, we cannot exclude false positive findings due to multiple 
testing. The biological plausibility of the TDF signal is not clear yet 
and remains to be elucidated. DEXA scans and measurements of 
vitamin D levels were not systematically done in all participants.
In conclusion, we confirm previously recorded AVN risk 
factors such as heterosexual HIV acquisition, moderate/severe 
Table  3. Uni- and Multivariable Conditional Logistic Regression of 
Avascular Bone Necrosis in 74 Cases and 145 Concurrent Controls
Factor
Univariable 
Model
OR (95% CI) P Value
Multivariable 
Modelsa
OR (95% CI) P Value
Transmission risk group 
MSM
1
Heterosexual 4.2 (1.7–10) .002 3.5 (1.1–10) .027
Intravenous drug use 2.8 (1.2–6.5) .014 1.9 (0.61–5.8) .268
Age per 10 y 0.84 (0.61–1.2) .29 0.67 (0.43–1.0) .073
Alcohol consumptionb 3.0 (1.6–5.8) .001 2.7 (1.3–5.7) .008
Corticosteroid usec 4.1 (1.4–12) .009 3.4 (0.97–12) .057
CD4 nadir <200 cells/µL 1.9 (0.99–3.7) .054 1.4 (0.63–3.2) .392
Log10 maximal HIV-1 
viral load
3.6 (0.89–15) .071 1.6 (0.41–6.6) .491
Pancreatitis 4.0 (1.0–16) .05 3.0 (0.66–14) .153
Hyperlipidemiad 3.8 (1.6–9.0) .002 3.6 (1.4–9.6) .010
Smoking, >20 pack-years 1.6 (0.94–2.8) .081 1.2 (0.59–2.63) .565
Testosterone use 0.40 (0.09–1.8) .237 0.38 (0.07–2.2) .279
Abbreviations: CI, confidence interval; OR, odds ratio. 
aMultivariable models were adjusted for transmission risk group, age, alcohol consump-
tion, use of corticosteroids, CD4 nadir, maximum viral load, pancreatitis, hyperlipidemia, 
smoking, and testosterone use. 
bAlcohol use: moderate (female 20–40 g/d, male 40–60 g/d) and severe use (female 
>40 g/d, male >60 g/). 
cCorticosteroid intake for more than 3 months. 
dHyperlipidemia: cholesterol >5 mmol/L and/or triglyceride >2 mmol/L.
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alcohol consumption [10, 21], hyperlipidemia, and corticoster-
oid use >3 months (trend) [5, 8, 10, 12, 21]. Our observation 
that TDF contributes to AVN is potentially worrisome and 
needs to be confirmed in other patient populations.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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